Your browser doesn't support javascript.
loading
The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia.
Rodríguez-Hernández, Guillermo; Casado-García, Ana; Isidro-Hernández, Marta; Picard, Daniel; Raboso-Gallego, Javier; Alemán-Arteaga, Silvia; Orfao, Alberto; Blanco, Oscar; Riesco, Susana; Prieto-Matos, Pablo; García Criado, Francisco Javier; García Cenador, María Begoña; Hock, Hanno; Enver, Tariq; Sanchez-Garcia, Isidro; Vicente-Dueñas, Carolina.
Afiliación
  • Rodríguez-Hernández G; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
  • Casado-García A; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • Isidro-Hernández M; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
  • Picard D; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • Raboso-Gallego J; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
  • Alemán-Arteaga S; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • Orfao A; Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Blanco O; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
  • Riesco S; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • Prieto-Matos P; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
  • García Criado FJ; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • García Cenador MB; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • Hock H; Servicio de Citometría, Departamento de Medicina, CIBERONC (CB16/12/00400), and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
  • Enver T; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
  • Sanchez-Garcia I; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.
  • Vicente-Dueñas C; Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Front Cell Dev Biol ; 9: 704591, 2021.
Article en En | MEDLINE | ID: mdl-34336858
ABSTRACT
ETV6-RUNX1 is almost exclusively associated with childhood B-cell acute lymphoblastic leukemia (B-ALL), but the consequences of ETV6-RUNX1 expression on cell lineage decisions during B-cell leukemogenesis are completely unknown. Clinically silent ETV6-RUNX1 preleukemic clones are frequently found in neonatal cord blood, but few carriers develop B-ALL as a result of secondary genetic alterations. The understanding of the mechanisms underlying the first transforming steps could greatly advance the development of non-toxic prophylactic interventions. Using genetic lineage tracing, we examined the capacity of ETV6-RUNX1 to instruct a malignant phenotype in the hematopoietic lineage by cell-specific Cre-mediated activation of ETV6-RUNX1 from the endogenous Etv6 gene locus. Here we show that, while ETV6-RUNX1 has the propensity to trigger both T- and B-lymphoid malignancies, it is the second hit that determines tumor cell identity. To instigate leukemia, both oncogenic hits must place early in the development of hematopoietic/precursor cells, not in already committed B-cells. Depending on the nature of the second hit, the resulting B-ALLs presented distinct entities that were clearly separable based on their gene expression profiles. Our findings give a novel mechanistic insight into the early steps of ETV6-RUNX1+ B-ALL development and might have major implications for the potential development of ETV6-RUNX1+ B-ALL prevention strategies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Cell Dev Biol Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Cell Dev Biol Año: 2021 Tipo del documento: Article País de afiliación: España